All News
Many drugs in the horizon for #lupus @Lupusreference lecture #EULAR2024
Loved the timeline of all major drug -phase 2 and 3 drugs.
Need for new strategies in Lupus – outcomes and survival is plateauing!
@RheumNow https://t.co/Ue239woQJr
Links:
Bella Mehta bella_mehta ( View Tweet)
Clinical pearl in #SLE pregnancies #EULAR2024 Whats new in lupus session.
Measure Hydroxychloroquine levels! @RheumNow https://t.co/OnktkMSPR5
Bella Mehta bella_mehta ( View Tweet)
Lupus GPT - a chatbot which is much more relevant to Lupus - for patients and physician question etc. #EULAR2024 - Will be functional soon.
Looking forward to playing with this. #LLMs #ChatGPT
More to come. @RheumNow https://t.co/mGXG6A85Hx
Bella Mehta bella_mehta ( View Tweet)
Biomarkers in Lupus - Urine biomarkers @andreafava in #EULAR2024
We need these biomarkers to come in mainstream clinical practice if they work better than proteinuria. @RheumNow https://t.co/i7aeBx6qRR
Bella Mehta bella_mehta ( View Tweet)
@Lupusreference noted data suggests pulse IV methylprednisolone yields better outcomes for LN than adjustments of chronic oral steroids. #EULAR24 @RheumNow https://t.co/n93x036uIn
TheDaoIndex KDAO2011 ( View Tweet)
Precision medicine in Lupus is far from reality today. @Lupusreference @RheumNow #EULAR2024
Bella Mehta bella_mehta ( View Tweet)
Whats new in Lupus #EULAR2024 @Lupusreference lecture - many pearls.
Corticosteroids IV may be the way to go - referencing @AliDuarteMD team (better outcomes compared to oral steroids)
@RheumNow https://t.co/Fz1dZUVomF
Links:
Bella Mehta bella_mehta ( View Tweet)
Should we treat to target (T2T) for #SLE or just do SOC and gestalt (as most do in clinical practice)? @Lupusreference #EULAR24 @RheumNow
TheDaoIndex KDAO2011 ( View Tweet)
💊 Difficult-to-treat #SpA & #PsA
🤔 What are the challenges in assessing persistently active disease?
🗣️ Vinod Chandran takes us through the pearls and pitfalls in assessing D2T disease
🌎 Great to see #comorbidities highlighted
@RheumNow
#EULAR2024 https://t.co/x4jUTOC3li
Links:
Mrinalini Dey DrMiniDey ( View Tweet)
Dr. G Schett reported using CAR-T cell Rx in patients w/ 1. pedi-SLE 2. CNS lupus 3. refractory cases with success. Post- Rx vaccine response is fine, infection risk is less since pts no longer need steroids. He is still following the pts for relapse and AEs @RheumNow #EULAR24
TheDaoIndex KDAO2011 ( View Tweet)
Consider the source and type of pain when managing axSpA including nociplastic pain. Difficult to treat axSpA #EULAR2024 Rudwaleit M @RheumNow https://t.co/4rszIyw5V6
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
CAR-T effective B cell depletion preserving plasma cell function @rheumnow #EULAR2024 https://t.co/mYmwC2cV6e
Peter Nash drpnash ( View Tweet)
« CAR T cells can change the therapeutic scenario: a short treatment for a prolonged efficacy » says G. Schett
Are we finally looking at the « visionary scenario »?
@RheumNow #EULAR2024 https://t.co/tzfDormeIl
Aurelie Najm AurelieRheumo ( View Tweet)
@Janetbirdope @RheumNow #EULAR2024 JAK-i Debate
@drdavidliew (NOT in support of regulation)
- is the signal real? Query about replicability & data came from N. America. Not reflected on real-world data of enriched cohorts
- is the warning justified?
- are there unintended consequences?
@RheumNow https://t.co/TXUf90fqwN
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Asking the quintessential Australian question at #EULAR24 by @drdavidliew - does the ORAL surveillance study for JAKi *truly* pass the pub test?
@eular_org @Janetbirdope @RheumNow
What does #MedTwitter think? https://t.co/bqwPU8XX5S
Links:
Benjamin Sutu benjaminsutu ( View Tweet)
Pt with LN, endocarditis, pericarditis, arthritis, rash failed CTX, MMF, BEL, and SOC. She is 1000 days post CAR-T cell. Off immunomodulating drugs. #SLE in remission clinically and serologically. - Dr G Schett #EULAR24 @RheumNow https://t.co/3vdMtO6VWI
TheDaoIndex KDAO2011 ( View Tweet)
#EULAR2024 JAK-i Debate.
@Janetbirdope [Pro Regulatory Safety Measures]
- to do no harm esp since there are other alternatives
- supported by RCT
- although JAK-i have different structures, data from individual RCT + LTE showed similar rates of malignancy & MACE @RheumNow https://t.co/jQKQmHE9Fg
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Areas to consider in difficult to manage PsA and research agenda #EULAR2024 Chandran V @RheumNow https://t.co/sp4tkAivLa
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Significant proportion of patients in PsA do not achieve remission across the domains. This can be due to disease heterogeneity, domain differences, comorbidities. There is a need to study the use of combination ts and bDMARDs. Difficult to Manage PsA session #EULAR2024 Ribeiro,… https://t.co/Wt3jgtIR9N https://t.co/VzCApikqek
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Join us later for a some very exciting pieces of translational science across a AIRDs.
All these abstracts sharing one thing in common: tissue, tissue, tissue!
16:30-18:00 Room A8.2
@RheumNow #EULAR2024 https://t.co/HrHP5tmHDD
Aurelie Najm AurelieRheumo ( View Tweet)